諾和諾德
NVO50.370USD
+0.190+0.38%
收盤 12/15, 16:00（美東）報價延遲15分鐘
169.45B總市值
14.59本益比TTM
關於 諾和諾德 公司
諾和諾德是一家專注糖尿病護理的全球醫療健康公司，同時涉足藥物的發現、研發、生產與行銷。公司透過「糖尿病與肥胖護理」及「生物製藥」兩大業務運作。前者產品組合含胰島素、GLP-1 受體激動劑（Ozempic、Wegovy、Rybelsus 等） 、胰高血糖素等蛋白質類療法、蛋白質投遞系統與注射針頭，以及口服降糖藥；後者聚焦血友病護理、生長激素補充及激素替代治療。另有 Saxenda 專門針對臨床肥胖症。主要品牌包含 NovoLog/NovoRapid、NovoLog Mix/NovoMix、Prandin/NovoNorm、NovoSeven、Norditropin、Vagifem 等。公司藥品銷往逾一百八十個國家，全球商業體系由北美與國際運營兩大區域組成，透過臨床研究、製造網絡與市場渠道將療法帶給患者。
諾和諾德簡介
公司代碼NVO
公司名稱Novo Nordisk A/S
上市日期May 17, 1974
CEODoustdar (Maziar Mike)
員工數量76302
證券類型Depository Receipt
年結日May 17
公司地址Novo Alle 1
城市BAGSVAERD
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家Denmark
郵編2880
電話4544448888
網址https://www.novonordisk.com/
公司代碼NVO
上市日期May 17, 1974
CEODoustdar (Maziar Mike)
諾和諾德公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Cees de Jong
Dr. Cees de Jong
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Tania Sabroe
Ms. Tania Sabroe
Executive Vice President - People, Organisation & Corporate Affairs
Executive Vice President - People, Organisation & Corporate Affairs
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President, Chief Scientific Officer, Research & Development
Executive Vice President, Chief Scientific Officer, Research & Development
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Cees de Jong
Dr. Cees de Jong
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Total GLP-1
5.83B
49.92%
Obesity (Wegovy®)
2.97B
25.41%
Fast-acting insulin
689.86M
5.91%
Long-acting insulin
678.47M
5.81%
Rare blood disorders
470.23M
4.03%
其他
1.04B
8.92%
地區USD
名稱
營收
佔比
USA
6.53B
55.90%
Canada
2.50B
21.40%
Emerging Markets
1.15B
9.82%
APAC
852.83M
7.31%
Region China
651.28M
5.58%
業務
地區
業務USD
名稱
營收
佔比
Total GLP-1
5.83B
49.92%
Obesity (Wegovy®)
2.97B
25.41%
Fast-acting insulin
689.86M
5.91%
Long-acting insulin
678.47M
5.81%
Rare blood disorders
470.23M
4.03%
其他
1.04B
8.92%
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Capital International Investors
0.53%
Loomis, Sayles & Company, L.P.
0.48%
Putnam Investment Management, L.L.C.
0.41%
Fidelity Management & Research Company LLC
0.38%
Fisher Investments
0.31%
其他
97.91%
持股股東
持股股東
佔比
Capital International Investors
0.53%
Loomis, Sayles & Company, L.P.
0.48%
Putnam Investment Management, L.L.C.
0.41%
Fidelity Management & Research Company LLC
0.38%
Fisher Investments
0.31%
其他
97.91%
股東類型
持股股東
佔比
Investment Advisor
4.66%
Investment Advisor/Hedge Fund
2.41%
Research Firm
0.92%
Hedge Fund
0.38%
Pension Fund
0.33%
Bank and Trust
0.20%
Insurance Company
0.19%
Family Office
0.02%
Family Office
0.02%
其他
90.87%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
2793
305.60M
9.08%
-33.91M
2025Q2
2754
330.35M
9.82%
-31.19M
2025Q1
2769
336.08M
9.99%
-21.71M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
2023Q2
1692
293.83M
8.50%
+768.69K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Capital International Investors
11.62M
0.35%
+2.11M
+22.18%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
12.58M
0.37%
+187.79K
+1.52%
Jun 30, 2025
Fidelity Management & Research Company LLC
12.93M
0.38%
+3.95M
+44.01%
Jun 30, 2025
Fisher Investments
11.00M
0.33%
-870.32K
-7.33%
Jun 30, 2025
Folketrygdfondet
10.09M
0.3%
+572.63K
+6.01%
Jun 30, 2025
Managed Account Advisors LLC
8.81M
0.26%
+195.59K
+2.27%
Jun 30, 2025
Fayez Sarofim & Co.
10.50M
0.31%
-708.84K
-6.32%
Jun 30, 2025
Everett Harris & Co.
6.39M
0.19%
-13.84K
-0.22%
Jun 30, 2025
Parametric Portfolio Associates LLC
6.23M
0.19%
+587.70K
+10.42%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Roundhill GLP-1 & Weight Loss ETF
15.04%
VanEck Pharmaceutical ETF
14.55%
Amplify Weight Loss Drug & Treatment ETF
9.51%
The Opal International Dividend Income ETF
3.79%
TrueShares Low Volatility Equity Income ETF
3.21%
First Trust WCM International Equity ETF
2.68%
Invesco International Dividend Achievers ETF
1.8%
Putnam Focused Large Cap Value ETF
1.16%
SP Funds S&P World (ex-US) ETF
1.05%
ActivePassive International Equity ETF
0.95%
查看更多
Roundhill GLP-1 & Weight Loss ETF
佔比15.04%
VanEck Pharmaceutical ETF
佔比14.55%
Amplify Weight Loss Drug & Treatment ETF
佔比9.51%
The Opal International Dividend Income ETF
佔比3.79%
TrueShares Low Volatility Equity Income ETF
佔比3.21%
First Trust WCM International Equity ETF
佔比2.68%
Invesco International Dividend Achievers ETF
佔比1.8%
Putnam Focused Large Cap Value ETF
佔比1.16%
SP Funds S&P World (ex-US) ETF
佔比1.05%
ActivePassive International Equity ETF
佔比0.95%
分紅派息
近5年累計派現
21.09B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Aug 06, 2025
NVO.NB Interim Cash Dividend of gross USD 0.58432 paid on Aug 26, 2025 going ex on Aug 18, 2025
Aug 18, 2025
Aug 26, 2025
Aug 18, 2025
Feb 06, 2025
NVO.NB Final Cash Dividend of gross USD 1.142561 paid on Apr 08, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Apr 08, 2025
Mar 31, 2025
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Interim Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Final Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Interim Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Interim Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
Feb 22, 2021
NVO.NB Final Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021
Mar 29, 2021
Apr 07, 2021
Mar 26, 2021
查看更多
拆合股
公告日期
類型
比率
Aug 14, 2023
Split
1→2
公告日期
類型
比率
Aug 14, 2023
Split
1→2
常見問題
諾和諾德的前五大股東是誰？
諾和諾德的前五大股東如下：
Capital International Investors持有股份：11.62M佔總股份比例：0.35%。
Loomis, Sayles & Company, L.P.持有股份：12.58M佔總股份比例：0.37%。
Fidelity Management & Research Company LLC持有股份：12.93M佔總股份比例：0.38%。
Fisher Investments持有股份：11.00M佔總股份比例：0.33%。
Folketrygdfondet持有股份：10.09M佔總股份比例：0.30%。
Capital International Investors持有股份：11.62M佔總股份比例：0.35%。
Loomis, Sayles & Company, L.P.持有股份：12.58M佔總股份比例：0.37%。
Fidelity Management & Research Company LLC持有股份：12.93M佔總股份比例：0.38%。
Fisher Investments持有股份：11.00M佔總股份比例：0.33%。
Folketrygdfondet持有股份：10.09M佔總股份比例：0.30%。
諾和諾德的前三大股東類型是什麼？
諾和諾德 的前三大股東類型分別是：
Capital International Investors
Loomis, Sayles & Company, L.P.
Putnam Investment Management, L.L.C.
Capital International Investors
Loomis, Sayles & Company, L.P.
Putnam Investment Management, L.L.C.
有多少機構持有諾和諾德(NVO)的股份？
截至2025Q3，共有2793家機構持有諾和諾德的股份，合計持有的股份價值約為305.60M，占公司總股份的9.08% 。與2025Q2相比，機構持股有所增加，增幅為-0.74%。
哪個業務部門對諾和諾德的收入貢獻最大？
在FY2025Q2，Total GLP-1業務部門對諾和諾德的收入貢獻最大，創收5.83B，占總收入的49.92% 。
